Neuromyelitis Optica Spectrum Disorders
Conditions
Keywords
Neuromyelitis Optica Spectrum Disorders, extracelluar vesicles
Brief summary
This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and efficacy of intrathecal administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) for the treatment of neuromyelitis optica spectrum disorders.
Detailed description
This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The study consists of two parts: Part 1 is a dose-escalation study, while Part 2 is a dose-extension study based on the results of Part 1. Part 1 will follow a traditional 3+3 dose-escalation design, enrolling a total of 9 subjects. In Cohort 1, participants will receive 5 × 10\^9 particles; in Cohort 2, they will receive 1.5 × 10\^10 particles; and in Cohort 3, they will receive 3 × 10\^10 particles. If no dose-limiting toxicities (DLTs) are observed within 2 weeks after the initial administration, a new cohort will be enrolled at the next higher dose level. If DLTs are observed in 1 participant, another 2 participants will be treated at the same dose level. Dose escalation will cease if DLTs are observed in more than 33% of the participants. In Part 2, the remaining 60 participants will be randomized in a 2:1 ratio to the treatment and placebo groups, with the dose level determined by the Data Safety Monitoring Board based on the results of Part 1.
Interventions
DRUGExtracellular vesicles derived from human-induced neural stem cells for intrathecal injection
Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection（5×10\^9 particles）
DRUGA placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection
Extracellular vesicles placebo(5×10\^9 particles）
Sponsors
Tongji Hospital
iRegene Therapeutics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients must meet the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) and test positive for AQP4 antibodies. 2. Symptom onset occurred within 7 days prior to enrollment, with associated severe pain, lower limb motor dysfunction, or urinary/bowel impairment. 3. Males or Females aged between 18 and 65 years. 4. The Expanded Disability Status Scale (EDSS) score prior to the current disease episode is ≤ 4. 5. Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period. 6. Informed consent must be obtained from the patient or their legal representative, with a signed consent form must be provided.
Exclusion criteria
1. Abnormal laboratory indicators of the subjects need to be excluded, including, but not limited to, the following indicators: White Blood Cell Count \<3\*10\^9/L Neutrophil Count \<1.5\*10\^9/L \<1.5\*10\^9/L Hemoglobin \<85 \<85 g/L Platelet Count \<80\*10\^9/L \<80\*10\^9/L Serum Creatinine \>1.5\*ULN Total Bilirubin \>1.5\*ULN AST (GOT) \>3\*ULN ALT (GPT) \>3\*ULN Alkaline Phosphatase \>2\*ULN (AST = Aspartate Aminotransferase; GOT = Glutamic-Oxaloacetic Transaminase; ALT = Alanine Aminotransferase; GPT = Glutamic-Pyruvic Transaminase) 2. Any contraindications to lumbar puncture. 3. Pregnant or breastfeeding women, and patients with plans to conceive during the trial. 4. Patients with a known history of allergies to human-derived biological products or those with an allergic predisposition. 5. Patients who have undergone hematopoietic stem cell transplantation or lymphatic irradiation before enrollment. 6. Patients who have participated in any other clinical trial within the last 3 months. 7. Patients with severe comorbidities, including immunodeficiency or coagulation disorders. 8. Patients with active suicidal ideation within 6 months before screening or have a history of suicide attempts within 3 years before screening. 9. Patients with severe psychiatric symptoms that prevent clinical cooperation. 10. Patients with positive for alcohol addiction or drug abuse. 11. Patients with malignant tumors. 12. Patients who have experienced any of the following events within 12 weeks before enrollment: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Class IV heart failure. 13. Patients with persistent systemic infections and severe local infections. 14. Patients unable to undergo magnetic resonance imaging during the trial. 15. Patients deemed unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence and severity of all adverse events (AE) and serious adverse events (SAE) | Up to 6 month after treatment initiation | The assessment of adverse events and serious adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence and severity of all adverse events (AE) and serious adverse events (SAE) | Up to 18 month after treatment initiation | The assessment of adverse events and serious adverse events |
| Magnetic Resonance Imaging（MRI）scan of the brain and spinal cord at month 3、6 | Up to 6 month after treatment initiation | — |
| The score of Visual analogue scale（VAS） at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| Brief Pain Inventory - Short form (BPI-SF) at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The score of Expanded Disability Status Scale （EDSS） at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | The score of EDSS ranges from 0 to 10, and 10 represents the worst. |
| The score of Fecal Incontinence Severity Index (FISI) at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | The score of FISI ranges from 0 to 3, and 3 represents the worst. |
| The score of Hauser Ambulance Index （contains The timed 25-foot walk）at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | The score of HAI ranges from 1 to 11, and 11 represents the worst. |
| The score of Hamilton Despression Scale at month 1、3、6 compared with baseline and control group | Up to 6 month after treatment initiation | The score of Hamilton Depression Scale ranges from 0 to 81, and 81 represents the worst |
| The score of Hamilton Anxiety Scale at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | The score of Hamilton Anxiety Scale ranges from 0 to 56, and 56 represents the worst. |
| The Modified Rankin Scale (mRS) | Up to 6 month after treatment initiation | To assess mRS of subjects within month 1、3、6 after treatment initiation |
| The value of Quality of Life (EQ-5D-5L) at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) events at month 1、3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of Nfl、GFAP in the serum at month 1、3、6 compared with baseline and control group | Up to 6 month after treatment initiation | — |
| The value of white blood cell count in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of QAlb in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of Nfl in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of GFAP in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of IL-1β in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of IL-6 in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of TNF-α in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| The value of sTREM2 in cerebrospinal fluid at month 3、6 compared with baseline and control group. | Up to 6 month after treatment initiation | — |
| Examination of visual function at month 1、3、6 | Up to 6 month after treatment initiation | Orbital MRI and VEP (Visual evoked potential) |
| Optical coherence tomography (OCT) at month 3、6 | Up to 6 month after treatment initiation | — |
Countries
China
Contacts
CONTACTChuan Qin, MD
PRINCIPAL_INVESTIGATORDai-shi Tian, MD
Tongji Hospoital
PRINCIPAL_INVESTIGATORWei Wang, MD
Tongji Hospoital
PRINCIPAL_INVESTIGATORChuan Qin, MD
Tongji Hospital
Outcome results
None listed